About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT01942629

Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas

The p63 gene is a recently discovered member of the p53 family located at chromosome 3q27Many studies have reported that overexpression of p63 can mimic p53 activities by binding DNA, activating trans...

Lead sponsor: Rambam Health Care Campus•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Rambam Health Care Campus

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients who were treated at our institution for lung adenocarcinoma, breast adenocarcinoma, or pancreatic ductal adenocarcinoma.
•Available histopathological diagnosis of the malignancy.

Exclusion Criteria

•Patients with inoperable tumors.
•Patients with second primary tumor.
•Patients with pathological blocks not enough for future slicing.

Related studies

RECRUITINGPhase 1/2

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more

RECRUITINGPhase 1

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

NCT04521764 · Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, and more

RECRUITINGPhase 1/2

Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

NCT07627711 · Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced, and more

RECRUITINGPhase 3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07217717 · Pancreatic Ductal Adenocarcinoma (PDAC)

RECRUITINGPhase 2

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

NCT05528458 · Lung Adenocarcinoma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 16, 2013Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment300

Start dateOct 2013

Last updatedSep 16, 2013

Condition

Lung Adenocarcinoma Breast Adenocarcinoma Pancreatic Ductal Adenocarcinoma

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 16, 2013Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions